Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Blood (2024) 144 (Supplement 1): 684.

https://doi.org/10.1182/blood-2024-206163

Published: 2024

Journal Articles

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

Vivien Reinecke, Daniel Hofbauer, Jörg-Thomas Bittenbring, Christopher Lischer, Johannes Berges, Gina Nusser, Katrin Bitterer, Simon Voelkl, Dimitrios Mougiakakos, Andreas Mackensen, Heiko Bruns

Blood (2024) 144 (Supplement 1): 1153.

https://doi.org/10.1182/blood-2024-203108

Published: 2024

Journal Articles

CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Haroon Shaikh, Cindy Flamann, Carina Matos, Hla Ali, Michael AG Kern, Marina Kreutz, Maike Buettner-Herold, Christopher Lischer, Simon Voelkl, Christian Kellner, Katrin Bitterer, Domenica Saul, Ernst Holler, Alma Zernecke, Dimitrios Mougiakakos, Andreas Beilhack, Heiko Bruns

Blood (2024) 144 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2024-205870

Published: 2024

Journal Articles

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

Blood (2024) 144 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2024-207051

Published: 2024

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Blood (2023) 142 (Supplement 1): 220.

https://doi.org/10.1182/blood-2023-180547

Published: 2023

Journal Articles

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6871.

https://doi.org/10.1182/blood-2023-188830

Published: 2023

Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Blood (2022) 140 (Supplement 1): 4549–4551.

https://doi.org/10.1182/blood-2022-167632

Published: 2022

Journal Articles

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Blood (2022) 140 (Supplement 1): 7522–7523.

https://doi.org/10.1182/blood-2022-168874

Published: 2022

Journal Articles

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

Nina Eisenhauer, Maurizio Miano, Nora Naumann-Bartsch, Joerg Leyh, Paola Terranova, Claas Hinze, Michael Aigner, Helmut Wittkowski, Heiko Bruns, Stephan Ehl, Markus Metzler, Peter Arkwright, Andreas Mackensen, Anne Rensing-Ehl, Simon Voelkl

Blood (2022) 140 (Supplement 1): 11194.

https://doi.org/10.1182/blood-2022-168550

Published: 2022

Journal Articles

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Richard Pelzl, Sabrina Kübel, Paulina Klein, Franziska Gsottberger, Kerstin Wendland, Srdjan Petkovic, Valeska Brueckl, Rebecca Baur, Simon Voelkl, Andreas Mackensen, Krystelle Nganou-Makamdop, Fabian Müller

Blood (2022) 140 (Supplement 1): 6432–6433.

https://doi.org/10.1182/blood-2022-167216

Published: 2022

Journal Articles

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Hannah Reimann, Anita Natalie Kremer, Viktoria Blumenberg, Katja Schmidt, Michael Aigner, Andreas Kremer, Matthias Tenbusch, Heiko Bruns, Thomas Harrer, Georg Schett, Fabian Mueller, Andreas Mackensen, Marion Subklewe, Simon Voelkl

Blood (2022) 140 (Supplement 1): 10279–10280.

https://doi.org/10.1182/blood-2022-165968

Published: 2022

Journal Articles

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Blood (2022) 140 (Supplement 1): 9292–9293.

https://doi.org/10.1182/blood-2022-159955

Published: 2022

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Fabian Mueller, Simon Voelkl, Dimitrios Mougiakakos, Sebastian Boeltz, Michael Aigner, Regina Gary, Sascha Kretschmann, Soraya Kharboutli, Arnd Kleyer, David Simon, Wolf Rösler, Katharina M. Habenicht, Thomas H. Winkler, Gerhard Krönke, Georg Schett, Andreas Mackensen

Blood (2022) 140 (Supplement 1): 4562–4563.

https://doi.org/10.1182/blood-2022-165077

Published: 2022

Journal Articles

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Maximilian Alexander A Rohnert, Malte von Bonin, Michael Kramer, Philipp Ensel, Nadja Holtschke, Christoph Rollig, MD MSC, Martin Bornhäuser, MD, Veit Buecklein, MD, Marion Subklewe, MD, Stefan W Krause, Simon Voelkl, Tobias Berg, Michael A Rieger, Cornelia Brendel, Jörg Hoffmann, Nicole Hofmeister-Mielke, Richard F. Schlenk, Sylvie D Freeman, Uta Oelschlägel

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-138683

Published: 2020

Journal Articles

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Dimitrios Mougiakakos, MD, Simon Voelkl, PhD, Christian Bach, Andrej Stoll, Katrin Bitterer, Fabian Beier, MD, Jan Endell, Rainer Boxhammer, Jörg Thomas Bittenbring, MD, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 4064.

https://doi.org/10.1182/blood-2019-124886

Published: 2019

Journal Articles

Microenvironmental Triggers Induce a Chemoresistant, Differentiated Subset of S100A8/A9 high AML Cells Via the Jak/STAT3 Signaling Axis

Martin Boettcher, PhD, Konstantinos Panagiotidis, Kristin Mentz, Simon Voelkl, PhD, Heiko Bruns, PhD, Robert Slany, PhD, Andreas Mackensen, MD, Dimitrios Mougiakakos, MD

Blood (2019) 134 (Supplement_1): 2714.

https://doi.org/10.1182/blood-2019-129689

Published: 2019

Journal Articles

Human Double-Negative Regulatory T Cells Modulate Effector Functions of Conventional T Cells By Selectively Blocking mTOR Signaling

Tabea Haug, Michael Aigner, PhD, Heiko Bruns, PhD, Moritz Peuser, Dorothea Gebhardt, Jana Berger, Florentine Koppitz, Andreas Mackensen, MD, Simon Voelkl

Blood (2018) 132 (Supplement 1): 2410.

https://doi.org/10.1182/blood-2018-99-112943

Published: 2018

Journal Articles

Effect of Proinflammatory and Homeostatic Cytokines on the Functionality of Human Double-Negative Regulatory T Cells

Moritz Peuser, Tabea Haug, Michael Aigner, PhD, Andreas Mackensen, MD, Simon Voelkl

Blood (2018) 132 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2018-99-112977

Published: 2018

Journal Articles

Human Double-Degative Regulatory T Cells Modulate Differentiation and Function of Conventional T Cells By Disrupting mTOR Activity

Tabea Haug, Heiko Bruns, PhD, Michael Aigner, PhD, Andreas Mackensen, MD, Simon Voelkl, PhD

Blood (2017) 130 (Supplement 1): 3579.

https://doi.org/10.1182/blood.V130.Suppl_1.3579.3579

Published: 2017

Journal Articles

Human Double-Negative Regulatory T Cells Selectively Suppress mTOR Signaling and Metabolic Reprogramming of Conventional T Cells

Tabea Haug, Heiko Bruns, PhD, Michael Aigner, Andreas Mackensen, Simon Voelkl, PhD

Blood (2016) 128 (22): 3694.

https://doi.org/10.1182/blood.V128.22.3694.3694

Published: 2016

NARROW

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Microenvironmental Triggers Induce a Chemoresistant, Differentiated Subset of S100A8/A9 high AML Cells Via the Jak/STAT3 Signaling Axis

Human Double-Negative Regulatory T Cells Modulate Effector Functions of Conventional T Cells By Selectively Blocking mTOR Signaling

Effect of Proinflammatory and Homeostatic Cytokines on the Functionality of Human Double-Negative Regulatory T Cells

Human Double-Degative Regulatory T Cells Modulate Differentiation and Function of Conventional T Cells By Disrupting mTOR Activity

Human Double-Negative Regulatory T Cells Selectively Suppress mTOR Signaling and Metabolic Reprogramming of Conventional T Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only